Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
2,019 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Budde LE, Zhang H, Kim WS, et al. · J Clin Oncol · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, et al. · J Clin Oncol · 2020Clinical Trial, Phase I, Clinical Trial, Phase II
- Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
Ruella M, Paruzzo L, Chong ER, et al. · N Engl J Med · 2026Clinical Trial, Phase II, Randomized Controlled Trial
- Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.
Sorin M, Okde R, Goulet M, et al. · Lancet Haematol · 2026Systematic Review, Meta-Analysis
- Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Abramson JS, Solomon SR, Arnason J, et al. · Blood · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial.
Zhang MC, Tian S, Fu D, et al. · Cancer Cell · 2023Randomized Controlled Trial, Clinical Trial, Phase II
- Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Jacobson CA, Munoz J, Sun F, et al. · Transplant Cell Ther · 2024Meta-Analysis, Systematic Review
- Estimating the global burden of Epstein-Barr virus-related cancers.
Wong Y, Meehan MT, Burrows SR, et al. · J Cancer Res Clin Oncol · 2022Meta-Analysis, Review
- Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Gisselbrecht C, Glass B, Mounier N, et al. · J Clin Oncol · 2010Clinical Trial, Phase III, Comparative Study
- CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B, Lepage E, Briere J, et al. · N Engl J Med · 2002Clinical Trial, Comparative Study
- A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
Sehn LH, Martelli M, Trněný M, et al. · J Hematol Oncol · 2020Clinical Trial, Phase III, Comparative Study
- Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.
Kamdar M, Solomon SR, Arnason J, et al. · J Clin Oncol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.
Locke FL, Siddiqi T, Jacobson CA, et al. · Blood Adv · 2025Meta-Analysis, Systematic Review
- Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR, Dorris CS, Makambi KH, et al. · Blood Adv · 2023Meta-Analysis, Systematic Review
- Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.
Minson A, Verner E, Giri P, et al. · J Clin Oncol · 2025Clinical Trial, Phase II, Randomized Controlled Trial
- Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.
Matasar M, Li Z, Vassilakopoulos TP, et al. · J Clin Oncol · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.
Maruyama D, Goto H, Kumode T, et al. · Int J Clin Oncol · 2026Clinical Trial, Phase III, Randomized Controlled Trial
- Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data.
Bayly-McCredie E, Treisman M, Fiorenza S · Int J Mol Sci · 2024Systematic Review
- How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials.
Intzes S, Symeonidou M, Zagoridis K, et al. · Ann Hematol · 2024Meta-Analysis, Systematic Review
- Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Hagberg H, Gisselbrecht C · Ann Oncol · 2006Clinical Trial, Phase III, Multicenter Study
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Coiffier B, Thieblemont C, Van Den Neste E, et al. · Blood · 2010Comparative Study, Randomized Controlled Trial
- Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.
Lakhotia R, Melani C, Dunleavy K, et al. · Leuk Lymphoma · 2025Clinical Trial, Phase II, Research Support, N.I.H., Intramural
- Plasmablastic lymphoma: a systematic review.
Castillo JJ, Reagan JL · ScientificWorldJournal · 2011Systematic Review
- Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.
Spanjaart AM, Bakker M, de Vries R, et al. · Lancet Haematol · 2026Systematic Review, Meta-Analysis
- Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.
Michot JM, Bologna S, Bastie JN, et al. · Ann Oncol · 2026Clinical Trial, Phase III, Multicenter Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.